416 related articles for article (PubMed ID: 33248510)
21. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
22. Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
Heffernan A; Ma Y; Nayagam S; Chan P; Chen Z; Cooke GS; Guo Y; Liu C; Thursz M; Zhang W; Zhang X; Zhang X; Jia M; Hallett TB
PLoS One; 2021; 16(1):e0245288. PubMed ID: 33439903
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.
Chhatwal J; Chen Q; Wang X; Ayer T; Zhuo Y; Janjua NZ; Kanwal F
JAMA Netw Open; 2019 May; 2(5):e193613. PubMed ID: 31074817
[TBL] [Abstract][Full Text] [Related]
24. A model of the economic benefits of global hepatitis C elimination: an investment case.
Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
[TBL] [Abstract][Full Text] [Related]
25. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation.
Zhong H; Aaron A; Hiebert L; Serumondo J; Zhuo Y; Adee M; Rwibasira GN; Ward JW; Chhatwal J
Value Health; 2024 Jul; 27(7):918-925. PubMed ID: 38492923
[TBL] [Abstract][Full Text] [Related]
27. An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom.
Williams J; Vickerman P; Douthwaite S; Nebbia G; Hunter L; Wong T; Ruf M; Miners A
Value Health; 2020 Aug; 23(8):1003-1011. PubMed ID: 32828211
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
John-Baptiste A; Yeung MW; Leung V; van der Velde G; Krahn M
Pharmacoeconomics; 2012 Nov; 30(11):1015-34. PubMed ID: 23050771
[TBL] [Abstract][Full Text] [Related]
30. Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years.
Veracruz N; Gish RG; Cheung R; Chitnis AS; Wong RJ
Liver Int; 2022 Oct; 42(10):2145-2153. PubMed ID: 35753064
[TBL] [Abstract][Full Text] [Related]
31. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication.
Goyal A; Murray JM
Theor Popul Biol; 2016 Dec; 112():60-69. PubMed ID: 27594346
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of HCV testing approaches in low and middle income countries.
Morgan JR; Servidone M; Easterbrook P; Linas BP
BMC Infect Dis; 2017 Nov; 17(Suppl 1):697. PubMed ID: 29143681
[TBL] [Abstract][Full Text] [Related]
33. Research gaps in viral hepatitis.
Boyd A; Duchesne L; Lacombe K
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25054. PubMed ID: 29633564
[TBL] [Abstract][Full Text] [Related]
34. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
35. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
[TBL] [Abstract][Full Text] [Related]
36. Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model.
Xiao Y; Howell J; van Gemert C; Thompson AJ; Seaman CP; McCulloch K; Scott N; Hellard ME
J Viral Hepat; 2020 May; 27(5):526-536. PubMed ID: 31856377
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
Ryan M; Griffin S; Chitah B; Walker AS; Mulenga V; Kalolo D; Hawkins N; Merry C; Barry MG; Chintu C; Sculpher MJ; Gibb DM
AIDS; 2008 Mar; 22(6):749-57. PubMed ID: 18356605
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
40. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
